LOL Yes, that alleviates some of the worries. Sorry, I took a quick look at the pipeline and it looked like something still in P3 with results yet to be reported. Understood on your other concerns.
I was mistaken as the small-cap Australian company I was thinking of is actually targeting FGF5. Name is Cellmid. I don't take seriously at all as they have 1B (!) shares O/S, trade at 2.5 cents/share, and have just positioned their drug as part of some OTC product.
On the JAK side, I assume any of the JAK players could potentially have interest in alopecia unless there is a specific niche needed (JAK1/2/or 3?). Also, interesting that it looks like ACRS is partnered with RIGL. I'm assuming they got their whole JAK pipe for alopecia from RIGL.
I have always thought of CLVLY as at least one of the more legit small-cap Australian biotechs but would need to do more DD to think about any possible position.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.